Therapeutic benefit of a combined strategy using erythropoietin and endothelial progenitor cells after transient focal cerebral ischemia in rats

Neurological Research

Volumn 35, Issue 9, 2013, Pages 937-947

  Pellegrini, Lionel ^a,b   Bennis, Youssef ^a   Guillet, Benjamin ^a,b   Velly, Lionel ^a,b   Garrigue, Philippe ^a,b   Sabatier, Florence ^a,c   Dignat George, Françoise ^a,c   Bruder, Nicolas ^b   Pisano, Pascale ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Endothelial progenitor cells; Erythropoietin; Neuroprotection; Stem cells; Stroke

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HEMOGLOBIN; JANSSEN CILAG; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BRAIN INFARCTION SIZE; CELL TRANSPLANTATION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; HUMAN; HUMAN CELL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MODIFIED NEUROLOGICAL SEVERITY SCORE; NERVOUS SYSTEM DEVELOPMENT; NICK END LABELING; NONHUMAN; RAT; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; ERYTHROPOIETIN; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROGENESIS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885618962     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000235     Document Type: Article

References (39)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2001;123(4):e18-209.
2. Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Tervaert JW, Lodder J. Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts. Stroke. 2008;39(7):2158-65.
3. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke. 2001; 32(11):2682-8.
4. Newcomb JD, Ajmo CT Jr, Sanberg CD, Sanberg PR, Pennypacker KR, Willing AE. Timing of cord blood treatment after experimental stroke determines therapeutic efficacy. Cell Transplant. 2006;15(3):213-23.
5. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874-82.
6. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-9.
7. Shen LH, Li Y, Chen J, Cui Y, Zhang C, Kapke A, et al. Oneyear follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke. 2007;38(7):2150-6.
8. Moubarik C, Guillet B, Youssef B, Codaccioni JL, Piercecchi MD, Sabatier F, et al. Transplanted late outgrowth endothelial progenitor cells as cell therapy product for stroke. Stem Cell Rev. 2011;7(1):208-20.
9. Chu K, Park KI, Lee ST, Jung KH, Ko SY, Kang L, et al. Combined treatment of vascular endothelial growth factor and human neural stem cells in experimental focal cerebral ischemia. Neurosci Res. 2005;53(4):384-90.
10. Hanabusa K, Nagaya N, Iwase T, Itoh T, Murakami S, Shimizu Y, et al. Adrenomedullin enhances therapeutic potency of mesenchymal stem cells after experimental stroke in rats. Stroke. 2005;36(4):853-8.
11. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84-91.
12. Codaccioni JL, Velly LJ, Moubarik C Bruder NJ, Pisano PS, Guillet BA. Sevoflurane preconditioning against focal cerebral ischemia: inhibition of apoptosis in the face of transient improvement of neurological outcome. Anesthesiology. (2009;110(6):1271-8.
13. Cuccuini W, Poitevin S, Poitevin G, Dignat-George F, Cornillet-Lefebvre P, Sabatier F et al. Tissue factor upregulation in proinflammatory conditions confers thrombin generation capacity to endothelial colony-forming cells without influencing non coagulant properties in vitro. J Thromb Haemost. 2010;8(9):2042-52.
14. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993;24(1):117-21.
15. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-60.
16. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2004;18(5):683-92.
17. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39(5):1569-74.
18. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Yang N, et al. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl Int. 2007;20(2):174-83.
19. Burns TC, Steinberg GK. Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther. 2011;11(4):447-61.
20. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, et al. A systematic review and meta analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab. 2010;30(5):961-8.
21. Esneault E, Pacary E, Eddi D, Freret T, Tixier E, Toutain J, et al. Combined therapeutic strategy using erythropoietin and mesenchymal stem cells potentiates neurogenesis after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2008;28(9):1552-63.
22. Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther. 2010;128(3):445-59.
23. Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M, et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther. 2005;11(1):96-104.
24. Lladó J, Haenggeli C, Maragakis NJ, Snyder EY, Rothstein JD. Neural stem cells protect against glutamate-induced excitotoxicity and promote survival of injured motor neurons through the secretion of neurotrophic factors. Mol Cell Neurosci. 2004;27(3):322-31.
25. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198(6):971-5.
26. Vendrame M, Gemma C, de Mesquita D, Collier L, Bickford PC, Sanberg CD, et al. Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev. 2005;14(5):595-604.
27. Lee ST, Chu K, Jung KH, Kim SJ, Kim DH, Kang KM, et al. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain. 2008;131(Pt 3):616-29.
28. Belayev L, Khoutorova L, Zhao W, Vigdorchik A, Belayev A, Busto R, et al. Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke. 2005;36(5):1071-6.
29. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76(1): 105-16.
30. Byts N, Samoylenko A, Fasshauer T, Ivanisevic M, Hennighausen L, Ehrenreich H, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ. 2008;15(4):783-92.
31. Minnerup J, Wersching H, Brokinkel B, Dziewas R, Heuschmann PU, Nabavi DG, et al. The impact of lesion location and lesion size on poststroke infection frequency. J Neurol Neurosurg Psychiatry. 2010;81(2):198-202.
32. Stein A, Knödler M, Makowski M, Kühnel S, Nekolla S, Keithahn A, et al. Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction. BMC Cardiovasc Disord. 2010;17(10): 43.
33. Kim YJ, Jung YW. Systemic injection of recombinant human erythropoietin after focal cerebral ischemia enhances oligodendroglial and endothelial progenitor cells in rat brain. Anat Cell Biol. 2010;43(2):140-9.
34. Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S, et al. Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care. 2011;15(1):R40.
35. Byts N, Sirén AL. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med. 2009;21(1):4.
36. Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, Jiang A, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J Cereb Blood Flow Metab. 2008;28(7):1361-8.
37. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26(4):1269-74.
38. Viviani B, Bartesaghi S, Corsini E, Villa P, Ghezzi P, Garau A, et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain derived neurotrophic factor. J Neurochem. 2005;93(2):412-21.
39. Ohab JJ, Carmichael ST. Poststroke neurogenesis: emerging principles of migration and localization of immature neurons. Neuroscientist. 2008;14(4):369-80.